DBD vs VYX: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
DBD is the larger of the two ($1.70B market cap): the incumbent the market prices for continued execution (8.25x forward earnings, beta 1.24). VYX is the smaller challenger ($1.24B), priced similarly on forward earnings (8.38x): more room to run, but more to prove. If the story you believe is DBD's (Services mix and recurring revenue), DBD is the more direct way to own it; if it is VYX's (Platform backlog turning into revenue), VYX is.
DBD vs VYX: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | DBD | VYX | What it tells you |
|---|---|---|---|
| Market cap | $1.70B | $1.24B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 8.25 | 8.38 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 24.00 | 18.32 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 1.24 | 1.51 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 2% of range | 59% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.82 | 1.32 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how DBD and VYX affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DBD and VYX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DBD and VYX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Diebold Nixdorf (DBD) do?
Diebold Nixdorf makes the machines that move cash and check out shoppers: ATMs, cash recyclers, self-checkout systems, point-of-sale terminals, and kiosks, sold through two segments (Banking and Retail) alongside the Vynamic software suite and a large installed-base services business. It is the global leader in self-checkout shipments outside China and serves a majority of the world's largest banks and retailers, so its revenue is tied to bank branch modernization, cash-recycling adoption, and retail automation cycles rather than any single fast-growing end market.
What does NCR Voyix (VYX) do?
NCR Voyix is what remained of NCR Corporation after the October 2023 spin-off of the ATM business as NCR Atleos and the 2024 sale of the digital banking unit. It sells software and services that run checkout for retailers and restaurants: point-of-sale and self-checkout software for grocery, convenience and specialty retail, and the Aloha system used by restaurant chains and independents, plus payment processing and maintenance. At the end of the first quarter of 2026 it finished handing its self-checkout and POS hardware business to Ennoconn under an outsourced design and manufacturing model, so it now books a sales commission on hardware rather than the full device price. The company is headquartered in Atlanta and run by CEO James Kelly.
DBD vs VYX: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- DBD drivers: Services mix and recurring revenue; DN Series recyclers and margin uplift.
- VYX drivers: Platform backlog turning into revenue; Retail margin expansion.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The core hardware markets (ATMs, POS, self-checkout) are mature and grow at low single digits, so structural declines in cash usage and bank branch counts are a persistent headwind. For VYX, core revenue is shrinking.
DBD or VYX: which should you pick?
With growth, valuation and volatility this close (or not yet reported for one side), the drivers above are what separate DBD from VYX. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DBD and VYX guides.
DBD vs VYX: the full fundamentals
DBD. DBD trades around a $1.7 billion market cap with the stock near $51, still well above its August 2023 relisting price of about $20.57 but down from a 52-week high near $92 and close to its 52-week low. At roughly 8 times forward earnings and under 6 times EV to EBITDA, the multiple has compressed further since the October guidance cut, and the mean target of three analysts (about $85) sits far above the current price. Revenue growth remains modest (low to mid single digits), so the case now leans on memory costs easing in early 2027, free cash flow recovering in the fourth quarter and the new buyback.
VYX. With an enterprise value near $2.1 billion (market cap plus about $1.1 billion of debt, less $275 million of cash) and adjusted EBITDA guided to about $440 million, VYX trades just under 5x EBITDA and about 10x the midpoint of 2026 non-GAAP EPS guidance at the November 20, 2026 price of about $9.25. Those are low multiples for a company with roughly 80% recurring revenue, and they reflect shrinking core sales and doubts about how fast the platform backlog converts. GAAP earnings are much thinner: income from continuing operations was about $11 million for the first nine months of 2026. Preferred stock adds to the claims ahead of common shareholders. The seven analysts in Yahoo's consensus carry a mean target near $13.29 and expect about $1.09 of EPS in 2027.
Headline figures (approximate, November 2026): DBD shows revenue (ttm) ~$3.92B, q3 2026 revenue ~$991M (+~5% YoY); adjusted EPS $1.34 vs ~$1.31 expected, net income (ttm) ~$77M; ~9% operating margin, 2026 adj. ebitda guidance ~$490M to $510M, cut from $510M to $535M; VYX shows revenue (ttm) ~$2.41B (Q3 2026 ~$539M, -20% YoY on the hardware change, ~-3% excluding it), adjusted ebitda (ttm) ~$425M (FY2026 guide $432M to $447M), non-gaap eps (fy2026 guide) ~$0.89 to $0.92, market cap ~$1.26B (~$9.25 per share, ~136M shares, November 20, 2026).
The bottom line: DBD vs VYX
DBD and VYX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined DBD and VYX exposure against your real portfolio. It is not an investment adviser.
Wondering how DBD or VYX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Diebold Nixdorf
Ask Walnut's AI anything about DBD and see how it fits what you own.
FAQ
What is the difference between DBD and VYX?
+
Diebold Nixdorf makes the machines that move cash and check out shoppers: ATMs, cash recyclers, self-checkout systems, point-of-sale terminals, and kiosks, sold through two segments (Banking and Retail) alongside the Vynamic software suite and a large installed-base services business. NCR Voyix is what remained of NCR Corporation after the October 2023 spin-off of the ATM business as NCR Atleos and the 2024 sale of the digital banking unit. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is DBD or VYX the better stock?
+
Neither is universally better. DBD is the larger incumbent; VYX is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, DBD or VYX?
+
On forward P/E (as of November 2026), DBD trades at 8.25x and VYX at 8.38x, so DBD is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both DBD and VYX?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of DBD vs VYX?
+
DBD: The core hardware markets (ATMs, POS, self-checkout) are mature and grow at low single digits, so structural declines in cash usage and bank branch counts are a persistent headwind. The company competes with well-capitalized rivals like NCR Atleos, NCR Voyix, Hyosung, and Glory, which pressures pricing on commoditizing hardware. Revenue is global with meaningful exposure to Europe and emerging markets, adding currency and macro sensitivity, and lumpy hardware order timing can make any single quarter volatile. Having so recently emerged from Chapter 11, the market is still assessing whether the improved margins are durable, and the stock has already re-rated substantially off its emergence price, leaving less margin for disappointment. Execution missteps on large rollouts or a slowdown in recycler adoption could quickly compress the margin story the valuation now assumes. Component costs, including memory, are now a demonstrated swing factor: elevated memory prices and a mix shift toward lower-margin retail products drove the October 2026 guidance cut, about $25 million of net headwinds for the year, and operating margin fell to about 3.9% in the third quarter from 7.8% a year earlier. The stock fell about 13% the day after that report and was down about 27% over the month to November 20, even though the quarter beat estimates. VYX: Core revenue is shrinking. Excluding the hardware change, revenue fell about 3% in the third quarter after growing about 1% in the second, and guidance now points to the low end of the range. Recurring revenue growth slowed to about 1% from 3%. The $440 million of remaining contract value is largely cancellable, since most contracts allow termination for convenience, and the company itself says it may not recognize all of it. Restaurant results depend on Aloha Next shipping on schedule; payment sites are already declining and segment EBITDA is down for the year. Competition is intense, from cloud-native restaurant systems like Toast to Oracle in large enterprises. The company carries about $1.1 billion of debt and a Series A preferred stock ahead of common holders, plus legacy environmental liabilities at the Fox River and Kalamazoo River sites (shared in part with NCR Atleos). It has also absorbed a 2023 ransomware attack on its Aloha cloud and about $34 million of fraudulent ACH disbursements, of which about $16 million had been recovered by September 30, 2026. The stock fell to about $6 in late 2025 and early October 2026 before recovering to about $9.25 by November 20, so swings of 30% to 40% have been common.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell DBD or VYX; figures are approximate and dated (as of November 2026). Verify current data before investing.